Triple-Drug attack aims to outsmart mantle cell lymphoma

NCT ID NCT04783415

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase II trial tests a combination of three targeted drugs—acalabrutinib, umbralisib, and ublituximab—in people with previously untreated mantle cell lymphoma. The drugs work by blocking signals that help cancer cells grow and by helping the immune system attack them. The study focuses on how many patients achieve a complete response after six cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of acalabrutinib, umbralisib, and ublituximab
What this could lead to: If successful, this combination could offer a more effective, chemotherapy-free treatment option for older or less fit patients with mantle cell lymphoma.
What could go wrong: This is a small, early-phase trial (12 participants) with no control group, so results may not generalize. The combination may also cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.